0.2896 -0 (-0.14%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.61 | 1-year : | 0.86 |
Resists | First : | 0.52 | Second : | 0.73 |
Pivot price | 0.29 | |||
Supports | First : | 0.19 | Second : | 0.15 |
MAs | MA(5) : | 0.3 | MA(20) : | 0.3 |
MA(100) : | 0.36 | MA(250) : | 0.76 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 50.5 | D(3) : | 54.5 |
RSI | RSI(14): 48.4 | |||
52-week | High : | 1.66 | Low : | 0.19 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AKLI ] has closed above bottom band by 48.2%. Bollinger Bands are 20.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.31 - 0.31 | 0.31 - 0.31 |
Low: | 0.28 - 0.28 | 0.28 - 0.28 |
Close: | 0.29 - 0.29 | 0.29 - 0.29 |
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
Thu, 28 Mar 2024
Akili, Inc. (NASDAQ:AKLI) Short Interest Update - Defense World
Mon, 11 Mar 2024
Akili executive compensation drops in 2023 - Boston Business Journal - The Business Journals
Thu, 29 Feb 2024
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Yahoo Finance
Tue, 27 Feb 2024
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version ... - Business Wire
Mon, 26 Feb 2024
Akili's ADHD device submitted for Japanese approval, stock rallies 130% (NASDAQ:AKLI) - Seeking Alpha
Mon, 26 Feb 2024
Why Is Akili (AKLI) Stock Up 110% Today? - InvestorPlace
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Healthcare - Information Services
|
|
Shares Out | 0 (M) |
Shares Float | 79 (M) |
Held by Insiders | 2.611e+007 (%) |
Held by Institutions | 23.2 (%) |
Shares Short | 62 (K) |
Shares Short P.Month | 0 (K) |
EPS | -6.418e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -1 % |
Return on Assets (ttm) | 551.7 % |
Return on Equity (ttm) | -35.9 % |
Qtrly Rev. Growth | 1.68e+006 % |
Gross Profit (p.s.) | 280.39 |
Sales Per Share | -34.31 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -0.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -58 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | 0.79 |
Dividend | 0 |
Forward Dividend | 820030 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |